Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica

L. Pulsatelli, G. Peri, P. Macchioni, L. Boiardi, C. Salvarani, F. Cantini, A. Mantovani, R. Meliconi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

Original languageEnglish
Pages (from-to)756-758
Number of pages3
JournalClinical and Experimental Rheumatology
Volume28
Issue number5
Publication statusPublished - 2010

Fingerprint

Polymyalgia Rheumatica
Serum
Recurrence
Arteritis
Adrenal Cortex Hormones
Enzyme-Linked Immunosorbent Assay
Therapeutics

Keywords

  • Biological marker
  • Polymyalgia reumatica
  • PTX3

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica. / Pulsatelli, L.; Peri, G.; Macchioni, P.; Boiardi, L.; Salvarani, C.; Cantini, F.; Mantovani, A.; Meliconi, R.

In: Clinical and Experimental Rheumatology, Vol. 28, No. 5, 2010, p. 756-758.

Research output: Contribution to journalArticle

@article{412c9ef653394166b8b9c7b8974ff2a8,
title = "Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica",
abstract = "Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.",
keywords = "Biological marker, Polymyalgia reumatica, PTX3",
author = "L. Pulsatelli and G. Peri and P. Macchioni and L. Boiardi and C. Salvarani and F. Cantini and A. Mantovani and R. Meliconi",
year = "2010",
language = "English",
volume = "28",
pages = "756--758",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "5",

}

TY - JOUR

T1 - Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica

AU - Pulsatelli, L.

AU - Peri, G.

AU - Macchioni, P.

AU - Boiardi, L.

AU - Salvarani, C.

AU - Cantini, F.

AU - Mantovani, A.

AU - Meliconi, R.

PY - 2010

Y1 - 2010

N2 - Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

AB - Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

KW - Biological marker

KW - Polymyalgia reumatica

KW - PTX3

UR - http://www.scopus.com/inward/record.url?scp=78650580840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650580840&partnerID=8YFLogxK

M3 - Article

C2 - 20822713

AN - SCOPUS:78650580840

VL - 28

SP - 756

EP - 758

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 5

ER -